drugset / Trial / NCT01955980

Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis

NCT01955980

Phase 1/2 Completed 19 enrolled Pari Pharma GmbH
RandomizedParallel-groupOpen-labelTreatment

Summary

The study should create data for the selection of a clinically relevant endpoint to assess the potential of Buparid/PARI SINUS to postpone sinus surgery in patients with chronic Rhinosinusitis.

Timeline

Start
2015-10-27
Primary completion
2018-09-27
Completion
2021-07-29

Drugs

EvaluationDrugModalityDoseRoute
Comparator Budesonide Small molecule 50 ug Inhaled
Comparator Budesonide Small molecule 1 mg Inhaled